IPX203 shows sustained safety, efficacy in RISE-PD extension trial

Using IPX203, an extended-release formulation of carbidopa/levodopa (CD/LD), was associated with a sustained control of symptoms for Parkinson’s disease patients who participated in the open-label extension of the RISE-PD Phase 3 trial. Final results from the nine-month extension study (NCT03877510) indicate dose adjustments and side effects were…

Low oxygen may help to ease symptoms in Parkinson’s: Report

Exposure to low oxygen may help to ease the symptoms of Parkinson’s disease — but a lot more research is needed to conclusively determine the safety and effectiveness of this strategy for use among people with the neurodegenerative disorder, according to a new report. “From a clinical perspective, hypoxia…

Don’t Store Your Medicine in the Medicine Cabinet!

Managing medications is a common responsibility for those with Parkinson’s disease and many other conditions. According to Georgetown University’s Health Policy Institute, more than 131 million people — 66% of U.S. adults — use prescription drugs. With Parkinson’s disease, managing medications is a balancing act required for us to…

#AAN2018- Inbrija Reduces Parkinson’s Off Periods, Phase 3 Trial Shows

Inbrija reduces Parkinson’s symptoms when standard treatments wear off, and decreases the length of these off periods, a Phase 3 clinical trial shows. The therapy’s developer, Acorda Therapeutics, will present the results at the American Academy of Neurology annual meeting in Los Angeles, April 21-27. Parkinson’s News Today will be covering…